<DOC>
	<DOC>NCT00326716</DOC>
	<brief_summary>To determine what dosing regimen of atazanavir (ATV) / ritonavir (RTV) produces adequate drug exposure during pregnancy compared to drug exposure in historical data in human immunodeficiency virus (HIV) infected participants.</brief_summary>
	<brief_title>Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
	<criteria>HIVinfected pregnant women &gt; 18 years of age Between week 12 and 32 gestation CD4 &gt; 200 cells/mmÂ³ Treatmentnaive with HIV RNA &gt; 400 c/mL, on HAART with HIV RNA &lt;50 c/mL, or previously treated with ATV (&lt; 3 weeks) with HIV RNA&gt;400 c/mL</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>HIV-1 infected pregnant women, either treatment naive or on ATV/RTV combined with ZDV/3TC</keyword>
</DOC>